From the Division of Hospital Medicine, Emory University School of Medicine, Atlanta, Georgia.
South Med J. 2022 Jan;115(1):8-12. doi: 10.14423/SMJ.0000000000001344.
Before the coronavirus disease 2019 (COVID-19) pandemic, vaping-related illness was the prevailing public health concern. The incidence of vaping-related illnesses-mainly e-cigarette, or vaping, product use-associated lung injury (EVALI)-went from a peak in September 2019 to a low in February 2020, and the Centers for Disease Control and Prevention decided to discontinue the collection of EVALI case reports. Despite the decrease in EVALI with the arrival of COVID-19, EVALI should still be considered a differential diagnosis for people with COVID-19 for reasons outlined in this review. This narrative review describes vaping devices, summarizes the adverse health effects of vaping on the lungs and other systems, considers the potential interplay between vaping and COVID-19, and highlights gaps in knowledge about vaping that warrant further research.
在 2019 年冠状病毒病（COVID-19）大流行之前，与蒸气相关的疾病是主要的公共卫生关注点。蒸气相关疾病的发病率 - 主要是电子烟或蒸气产品相关的肺损伤（EVALI） - 从 2019 年 9 月的高峰降至 2020 年 2 月的低点，疾病控制和预防中心决定停止收集 EVALI 病例报告。尽管随着 COVID-19 的到来，EVALI 的发病率有所下降，但出于本综述中概述的原因，EVALI 仍应被视为 COVID-19 患者的鉴别诊断。本叙述性综述描述了蒸气设备，总结了蒸气对肺部和其他系统的不良健康影响，考虑了蒸气与 COVID-19 之间的潜在相互作用，并强调了关于蒸气的知识差距，这些差距需要进一步研究。
